The pipeline for new pain drugs has grown perilously thin in recent years with a slate of key clinical trial failures. Only a few small players are still actively engaged in developing new therapies to replace the aging therapeutics that now dominate the market, especially after Pfizer’s last setback on an anti-NGF drug, finally closing that chapter of new drug development. Endpoints News will take a close look at the conditions that are limiting access to new drugs and the intense medical need to find drugs that can do a better job for an aging population. Lei Lei Wu will dig in to explain what’s happening here.

Lei Lei Wu
NEWS REPORTER, Endpoints News

Jan Adams
Presenting Speaker
Jan Adams
Chief Scientific Officer, Grünenthal

Always driven to improve patients’ lives, Jan Adams has built up more than 15 years of experience in healthcare and biopharmaceuticals and took over the role of CSO in 2020. Under his leadership, Grünenthal transformed its R&D strategy and operating model and significantly strengthened its pipeline of highly innovative non-opioid pain assets.

Jan joined Grünenthal in July 2017 as Head of Corporate Strategy and Portfolio Management, working at the interface between strategy, research, development, and commercial. Prior to joining Grünenthal, he served in roles with increasing levels of responsibility at Novartis and Takeda, as well as within McKinsey & Company’s global Pharmaceutical and Medical Products practice.

Click here to find additional information and registration details.

Related Content

Endpoints at #DIA23

Endpoints at #DIA23

The political issues circling the FDA this year could potentially ripple into biopharma on a scale that’s never been seen before. All eyes are on the FDA’s response to recent court rulings around the abortion pill mifepristone — and the potential effects on other approvals that might be questioned. What does the future look like, exactly? Join Endpoints’ Senior Editor Zachary Brennan in an expert panel to unpack what may come next. We’ll also touch on how the FDA is looking for new ways to spur more rare disease drug development with a fireside chat.